Boehringer Ingelheim pursuing health care innovation

Boehringer IngelheimIn future patients with certain diseases, especially chronic ones, should be treated in a more holistic approach beyond drug treatment only. Thus Boehringer Ingelheim is concentrating on new business models and healthcare innovation and just signed a contract with the US company Healthrageous, Inc., a digital health management company.

Both companies will evaluate in a pilot study a lifestyle behavior modification program to improve the health status of people with diabetes Type 2. Study participants will experience a digital technology intervention combining digital coaching and a wireless glucose meter transmitting data to clinical monitors. The Internet-based tool will allow an evaluation of the intervention on changes in lifestyle behaviors, glucose control, additional medical parameters and medication adherence.

"Boehringer Ingelheim is known for innovation in research and development and for bringing high quality medications quickly to the market. But we are also committed to a "beyond pill" approach in health care. We have to pursue a new approach to see the patient with all his or her aspirations but also limitations. We need to find suitable answers that will benefit not only the patients and their family but also the whole society in so far that healthier patients lead a more satisfactory life and can contribute to society for longer." said Bert Tjeenk-Willink, Member of the Board of Managing Directors of Boehringer Ingelheim. "This first initiative offering a comprehensive digital platform for Type 2 diabetes will help us to better understand what motivates individuals to become and remain engaged in self-managing their health. We are delighted to be working with Healthrageous here. Boehringer Ingelheim will engage in many more initiatives of that kind."

An estimated 366 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95% of all diabetes cases. The number is expected to grow considerably in the next years due to unhealthy lifestyles. Conclusions from findings in Behavioural Science show that in most chronic medical conditions and diseases such as diabetes, Chronic Obstructive Pulmonary Disease (COPD) or high blood pressure interventions with respect to drug adherence, lifestyle changes in nutrition, physical exercises, stress reduction and can bring about measureable improvements. The most important aspect, however, is that the patient sticks to a chosen regimen and properly manages his/her lifestyle change.

The goal of the new diabetes program is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier and more effective. During the collaboration, in a first phase 200 adults in the U.S. diagnosed with Type 2 diabetes for at least six months will have access to Healthrageous' digital diabetes self-management program. The web and smartphone delivered program will include a personalized action plan with health behavior improvement goals, biometric feedback to demonstrate goal achievement and milestones, digital coach interaction, recognition and incentives for progress, supply and strip refill ordering, medication reminders, and social networking support. If the results show the expected benefits, the program will be expanded to encompass up to one thousand patients in different countries.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...